Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 9, Pages 2648
Publisher
MDPI AG
Online
2020-09-16
DOI
10.3390/cancers12092648
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis.
- (2020) Laura M. Spring et al. CLINICAL CANCER RESEARCH
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and pooled analysis of transcriptomic data
- (2019) Alexios Matikas et al. CLINICAL CANCER RESEARCH
- PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
- (2019) Planes-Laine et al. Cancers
- CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer
- (2019) Bruna Cerbelli et al. VIRCHOWS ARCHIV
- Advances in the systemic treatment of triple-negative breast cancer
- (2018) J.M. Lebert et al. Current Oncology
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
- (2018) Angela Santonja et al. Oncotarget
- Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
- (2018) Bharathi Vennapusa et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).
- (2018) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review
- (2017) Rong Wang et al. Oncotarget
- Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab
- (2017) Jinhua Ding et al. Oncotarget
- PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
- (2017) Bruna Cerbelli et al. Biomed Research International
- Intratumoral CD8 + T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity
- (2017) Brendan L. Horton et al. Cancer Immunology Research
- The genomic landscape of breast cancer and its interaction with host immunity
- (2016) Stephen Luen et al. BREAST
- Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
- (2016) Marius Ilie et al. VIRCHOWS ARCHIV
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer
- (2015) Patricia Cortazar et al. ANNALS OF SURGICAL ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
- (2013) A N Seo et al. BRITISH JOURNAL OF CANCER
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
- (2013) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy
- (2012) Nehmat Houssami et al. EUROPEAN JOURNAL OF CANCER
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
- (2012) Tatiana M. Prowell et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD73: a potent suppressor of antitumor immune responses
- (2012) Paul. A. Beavis et al. TRENDS IN IMMUNOLOGY
- Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients
- (2011) Xiangnan Kong et al. EUROPEAN JOURNAL OF CANCER
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
- (2010) L. Zitvogel et al. CLINICAL CANCER RESEARCH
- Challenges, controversies, breakthroughs
- (2010) Lisa Hutchinson Nature Reviews Clinical Oncology
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
- (2010) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
- (2008) Priya Rastogi et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started